Aug. 11 at 11:57 PM
Mineralys Therapeutics shares fell in after-hours trading after the biopharmaceutical company reported a significantly wider-than-expected Q2 2026 loss, with a loss of
$2.85 per share versus the
$2.63 analyst consensus, compared with a
$0.47 loss in Q1. The disappointing result was driven mainly by a sharp increase in operating expenses as the company advances toward the commercial launch of lorundrostat.
R&D expenses surged to
$221.4 million, up from
$38.3 million a year earlier, largely due to a
$200 million upfront payment to Tanabe in June to acquire future royalty obligations for lorundrostat. G&A expenses also climbed to
$24.7 million from
$8.5 million, highlighting the rising costs associated with commercialization.
Despite the earnings miss, Mineralys’ regulatory outlook remains intact. The FDA has set Dec. 22, 2026, as the PDUFA decision date for lorundrostat, while CEO Jon Congleton said commercial preparations remain on track.
$MLYS